Inmed provides update on management changes

Vancouver, british columbia, nov. 17, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces that sarah li has been promoted to vice president of accounting and controller at inmed. ms. brenda edwards will be transitioning out of her position as interim chief financial officer at the company effective november 20, 2022.  ms. edwards joined the company in an interim contract role to assist the company with financial reporting matters following the retirement of the company's former chief financial officer in march 2022.
INM Ratings Summary
INM Quant Ranking